<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01451268</url>
  </required_header>
  <id_info>
    <org_study_id>CLBH589 BDE05T</org_study_id>
    <nct_id>NCT01451268</nct_id>
  </id_info>
  <brief_title>Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)</brief_title>
  <acronym>PANOBEST</acronym>
  <official_title>Phase I/II Study With Oral Panobinostat Maintenance Therapy Following Allogeneic Stem Cell Transplantation in Patients With High Risk MDS or AML (PANOBEST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's primary objective is to determine the maximum tolerated dose (MTD) and
      dose-limiting toxicity (DLT) of Panobinostat when administered within 150 days after
      hematopoietic stem cell transplantation (HSCT) and given in conjunction with standard
      immunosuppressive therapy after HSCT for patients with high-risk Myelodysplastic Syndrome
      (MDS) or Acute Myeloid Leukemia (AML).

      Secondary objectives are

        -  To determine safety and tolerability of panobinostat

        -  To determine overall and disease-free survival at 12 months after HSCT

        -  To evaluate immunoregulatory properties of panobinostat

        -  To evaluate patient-reported health-related quality of life (HRQL)

      The hypothesis of this study is that panobinostat can be an effective drug in preventing
      relapse of MDS and AML patients with high-risk features after hematopoietic stem cell
      transplantation with reduced-intensity conditioning (RIC-HSCT) while at the same time
      reducing graft-versus-host disease (GvHD) with preservation of graft-versus-leukemia (GvL)
      effect.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2011</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) of panobinostat</measure>
    <time_frame>after 28 days of administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-limiting toxicity (MTD) of Panobinostat</measure>
    <time_frame>after 28 days of administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of hematologic relapse and death</measure>
    <time_frame>one year after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reconstitution of the immune system as measured by changes in numbers, ratio, phenotype and activation state of peripheral blood cell populations during panobinostat therapy</measure>
    <time_frame>patients will be followed for up to 2 years depending on the duration of study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to complete donor chimerism</measure>
    <time_frame>patients will be followed for up to 2 years depending on the duration of study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of extensive chronic GvHD</measure>
    <time_frame>one year after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete donor chimerism</measure>
    <time_frame>patients will be followed for up to 2 years depending on the duration of study participation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of severe acute GvHD</measure>
    <time_frame>one year after HSCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient-reported health-related quality of life</measure>
    <time_frame>after 3 months of administration and one month after last intake of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Panobinostat Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Panobinostat Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <description>10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year</description>
    <arm_group_label>Panobinostat Arm A</arm_group_label>
    <other_name>LBH589</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panobinostat</intervention_name>
    <description>Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year</description>
    <arm_group_label>Panobinostat Arm B</arm_group_label>
    <other_name>LBH589</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  AML (except acute promyelocytic leukemia, AML M3) with high-risk features defined as
             one or more of the following criteria:

               -  refractory to or relapsed after at least one cycle of standard chemotherapy

               -  &gt; 10% bone marrow blasts at day 15 of the first induction cycle

               -  adverse risk cytogenetics including complex karyotype (≥ 3 abnormalities or
                  abnormalities of chromosomes 3, 5 or 7) regardless of stage

               -  secondary to MDS or radio-/chemotherapy or

          -  MDS RAEB according to the WHO classification or intermediate-2 or high-risk according
             to IPSS or

          -  Chronic myelomonocytic leukemia (CMML) with ≥ 5% bone marrow blasts and

               -  Allogeneic HSCT with reduced intensity conditioning (see Section 15.1 for
                  definition) performed within 60 - 150 days prior to study entry

               -  Complete hematologic remission documented by bone marrow aspiration within 28
                  days prior to study entry

        Exclusion Criteria:

          -  Active acute GvHD overall grade 2 - 4

          -  Prior treatment with a deacetylase (DAC) inhibitor

          -  Patients with impaired cardiac function or other concurrent severe and/or uncontrolled
             medical conditions

          -  Clinical symptoms suggesting central nervous system (CNS) leukemia

          -  Patient has an impairment of gastrointestinal (GI) function or GI disease that may
             significantly alter the absorption of oral panobinostat
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gesine Bug, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johann Wolfgang Goethe University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uct-frankfurt.de/content/studien/studien_im_ctcn/studienregister/index_ger.html</url>
    <description>Trial register of University Cancer Center Frankfurt, additional trial information</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2011</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospital</investigator_affiliation>
    <investigator_full_name>Gesine Bug</investigator_full_name>
    <investigator_title>Senior physician hematology</investigator_title>
  </responsible_party>
  <keyword>60 to 150 Days After Allogeneic Stem Cell Transplantation</keyword>
  <keyword>High Risk MDS</keyword>
  <keyword>MDS</keyword>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panobinostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

